Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON

OBJECTIVES: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib reduced the rate of decline in forced vital capacity (FVC) versus placebo, with adverse events that were manageable for most patients. An open-label extension trial, SENSCI...

Descripción completa

Detalles Bibliográficos
Autores principales: Allanore, Yannick, Vonk, Madelon C, Distler, Oliver, Azuma, Arata, Mayes, Maureen D, Gahlemann, Martina, James, Alexandra, Kohlbrenner, Veronika, Alves, Margarida, Khanna, Dinesh, Highland, Kristin B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Systemic Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664126/
https://www.ncbi.nlm.nih.gov/pubmed/35973804
http://dx.doi.org/10.1136/ard-2022-222564

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664126/
https://www.ncbi.nlm.nih.gov/pubmed/35973804
http://dx.doi.org/10.1136/ard-2022-222564

Ejemplares similares